|
LE Magazine May 2002

Page 2 of 3
Tocotrienols and breast cancer cell
growth
 |
| In cell culture, tamoxifen can
reduce estrogen receptor positive breast cancer cell
proliferation by 50%.When palm-oil derived tocotrienols
are added with tamoxifen, the dose of tamoxifen required
to induce 50% cell arrest was lowered by 75%. |
|
We now know that the form of vitamin E used in most
commercial preparations (alpha tocopherol acetate) has not
been shown to protect against breast cancer in humans. A
natural form of vitamin E called alpha tocopheryl succinate,
found in more expensive supplements, may provide some
protection. In test tube studies, the alpha tocopheryl
succinate form of vitamin E has been shown to inhibit breast
cancer cell growth. [22-35]
It is the tocotrienols, however, that have demonstrated the
most significant potential to not only reduce the incidence of
breast cancer, but also to inhibit existing breast cancer cell
propagation.
Tocotrienols have been shown to inhibit growth of estrogen
receptor positive breast cancer cells by as much as 50% in
culture.[36-39] In contrast, many
studies have found that alpha tocopherol does not influence
proliferation.[36,38-40] Even in
studies where alpha tocopherol was shown effective against
some breast cancer cell lines, the amount required for 50%
growth inhibition was more than 20 times higher than the
growth inhibitory concentrations of the tocotrienols.[37]
Comparison of multiple studies indicates that the growth
inhibitory effects of alpha tocopherol wears off,[41] whereas limited data suggest that
the growth inhibitory effects of the tocotrienols on breast
cancer cells is maintained or increases with duration of
exposure (in culture).[39,42]
Tamoxifen interferes with breast cancer cell proliferation
via several mechanisms, most notably by blocking estrogen
receptor sites on the cell membrane surface so that estrogen
cannot fuel hyper-proliferation. Tamoxifen is known to induce
side effects, but the documented effectiveness of the drug
causes many breast cancer patients to use it for two to five
years (or longer).
In cell culture, tamoxifen can reduce estrogen receptor
positive breast cancer cell proliferation by 50%. When
palm-oil derived tocotrienols are added with tamoxifen, the
dose of tamoxifen required to induce 50% cell arrest was
lowered by 75%.[37]
In estrogen receptor negative cancer cell lines, tamoxifen
can inhibit proliferation by 50%, but at much higher
concentrations. When tocotrienols are added, the dose of
tamoxifen required to inhibit cancer cell proliferation is
reduced by a much as 95%![37] When
alpha tocopherol is added to these breast cancer cell
cultures, it increases the amounts of tamoxifen required to
inhibit growth.[37]
These cell culture studies, showing that tocotrienols
dramatically potentiate the effects of tamoxifen, indicate the
desire to test a combination of tocotrienols and tamoxifen in
both estrogen receptor positive and estrogen receptor negative
breast cancer patients.
The study showing that alpha tocopherol increases the
amount of tamoxifen required to induce cell arrest implies
that breast cancer patients using tamoxifen may want to avoid
consuming high potencies of alpha tocopherol.
(Note: Life Extension magazine has previously reported that
vitamin D3 and melatonin work synergistically with tamoxifen
to inhibit breast cancer cell propagation.)
Tocotrienols induce breast cancer cell
death
The objective of any cancer therapy is to induce the cancer
cells to differentiate in a way that promotes programmed cell
death (apoptosis). Several studies indicate that tocotrienols
induce breast cancer cell apoptosis.[41-43]
When different kinds of live breast cancer cells were
injected into the mammary tissue of female mice, tocotrienols
were found to be growth inhibitory on each breast cancer cell
line tested. Although apoptosis could be achieved, the dose of
tocotrienol needed to induce 50% apoptosis was 2-4 times
higher than the dose of tocotrienol required to induce 50%
growth inhibition.[42]
It is interesting to note that the growth inhibition and
promotion of apoptosis occur preferentially in the cancerous
part of the breast so that healthy cells remain largely
unaffected.[42]
Can women obtain enough tocotrienols
to reduce breast cancer risk?
For those seeking to use tocotrienols to reduce breast
cancer risk, it is essential to quantify the optimal daily
dose. In humans not consuming tocotrienol supplements, the
average plasma concentration is less than 1 microgram per
liter of blood.[45-47] After
supplementation with a palm-oil concentrate containing about
78 milligrams of tocotrienols for four weeks, plasma
tocotrienol levels increased to 8.14 micrograms per liter of
blood (an eight-fold increase).[47]
|
Tocotrienols should be taken with food
For oil-soluble vitamin E to
be absorbed, it should be taken with some kind
of food. When people take oil-based vitamin E
preparations on an empty stomach, very little
makes its way into the bloodstream.
It is especially important
to take the tocotrienols with some form of oil
or fat-containing food. One study showed that
when tocotrienols are taken on an empty stomach,
absorption was reduced by an average of 64%.44
When taking gamma tocopherol
and/or tocotrienol vitamin E supplements, try
to take them with a meal or with fatty acid capsules
like fish oil (EPA-DHA), GLA, CLA etc.

|
|
This plasma concentration of 8.14ug/l of tocotrienol is
similar to the amount used to achieve an inhibitory effect on
the proliferation of estrogen receptor positive breast cancer
cells in vitro by 50%. The amount of tocotrienol to promote
apoptosis in vitro by 50% would be approximately 24ug/liter
according to this study.[2]
It is interesting to note that the body naturally
concentrates tocotrienols into breast adipose tissue. Based on
studies done to date, it is likely that breast adipose tissue
levels of tocotrienols will be 5 to 10 times greater than
plasma.[48-50] This indicates that
even lower tocotrienol supplementation might be adequate to
saturate breast adipose tissue with the amount of tocotrienols
that have inhibited breast cancer cell proliferation and
induced apoptosis in culture.
It is encouraging to know that the in vitro tests that
document the anti-cancer effects of tamoxifen also show
tocotrienols to have similar cell inhibitory properties.
Compared to tamoxifen, however, tocotrienols are safe. Human
studies have shown that daily doses of up to 240 mg of
tocotrienols for 16 months produce no adverse effects.[47,51,52] Further studies will
determine whether humans who saturate their breast adipose
tissue with tocotrienol from supplements will achieve a
reduced incidence of breast cancer. (Please note that it is
the palm-oil tocotrienols, and not rice-bran tocotrienols,
that have primarily demonstrated these anti-cancer
effects.)
Summary of findings
When reviewing all the published evidence, it does not
appear that alpha tocopherol vitamin E confers a protective
effect against breast cancer. Yet studies show that women who
consume foods high in other forms of vitamin E substantially
reduce their risk of contracting breast cancer (by as much as
90%).
A cardinal feature of breast tumors are rapidly
proliferating cells. Estrogen drugs promote
hyper-proliferation and this is one reason why these drugs may
quadruple the incidence of breast cancer. [53]
Studies of breast cancer cells in culture indicate that
tocotrienols have potent effects in inhibiting proliferation
and inducing apoptosis (cancer cell death). These studies show
that alpha tocopherol does not have this same benefit.
Alpha tocopherol acetate is the most common supplement form
of vitamin E, yet the evidence points to other forms of
vitamin E as being responsible for the dramatic reduction in
breast cancer incidence observed in large human studies.
We now know that the individual tocopherols and
tocotrienols have different biological activities as they
relate to their effects on cellular function. Gamma
tocopherol, for instance, has demonstrated significant cancer
prevention effects compared to alpha tocopherol.
The potential anti-cancer effects of gamma tocopherol and
the tocotrienols merits aggressive human clinical research to
determine if women who supplement with these unique forms of
vitamin E can reduce their risk of contracting breast cancer.
Further research should be conducted on breast cancer patients
to see if the addition of tocotrienols to tamoxifen improves
long-term survival rates.
Based on a review of all the published data, we cannot find
compelling evidence to indicate that standard (alpha
tocopherol) vitamin E supplements reduce breast cancer
incidence. While alpha tocopherol has been shown to protect
against a wide range of other diseases,[54-70] it would appear that the
tocotrienols are the ideal form of vitamin E to specifically
reduce breast cancer risk.
| For additional information about novel adjuvant ways of
preventing and treating breast cancer, refer to the Breast Cancer
Treatment Protocol.
|
Continued on Page
3 of 3
Back to
the Magazine Forum
|